EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats

Xiaohuan Gao, Guangzhao He, Yanzhi Bi, Hui Luo, Jing Wu, Yuanyuan Zu, Yun Ji, Jingping Yu

Frontiers in Pharmacology · 12.08.2026 · 17

DOI: 10.3389/fphar.2026.1875749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.08.2026. Verfasst von Xiaohuan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Central Operating Room, Changzhou Cancer Hospital, Changzhou, China. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Montmorillonite powder (MP) can adsorb pyrotinib and reduce its bioavailability. This study investigated the effects of different dosing intervals on the pharmacokinetic interaction between MP and pyrotinib in rats.

Methods

Eighteen male Sprague-Dawley rats were randomly assigned to three groups (n = 6/group): Control (pyrotinib alone), 0.5-h interval (MP given 0.5 h after pyrotinib), and 2.0-h interval (MP given 2.0 h after pyrotinib). Pyrotinib (10 mg/kg) was orally administered to all rats, followed by MP (240 mg/kg) or water (control) at designated time points. Blood samples were collected up to 24 h post-dose. Plasma pyrotinib concentrations were determined by a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated using WinNonlin.

Results

The 0.5-h interval group showed substantially reduced pyrotinib exposure, with area under the curve (AUC) from time zero to last time point (AUC last ) and AUC from time zero to infinity (AUC inf ) decreasing by 31.2% and 31.3%, respectively, indicating statistically significant reductions (90% CIs <1.0). C max reduction was 20.7%, which was not statistically significant (90% CI crossed 1.0). For the 2.0-h interval group, all GMRs were close to unity, but the wide 90% CIs (69.1%–137.6%) could not rule out a clinically meaningful impact.

Conclusion

In rats, MP administration at an insufficient dosing interval markedly compromises pyrotinib systemic exposure, whereas adequate temporal separation largely mitigates this interaction. These findings underscore the urgent need for dedicated clinical pharmacokinetic studies to define the optimal dosing interval in humans and to minimize the risk of subtherapeutic pyrotinib exposure in clinical practice.

Schlagwörter

Stichwörter der Autor:innen

drug-drug interactionliquid chromatography-tandem mass spectrometrymontmorillonite powderpharmacokineticspyrotinibrat

Autor:innen und Institutionen

  • Central Operating Room, Changzhou Cancer Hospital, Changzhou, China.
  • Office of Clinical Trial Institution, Changzhou Cancer Hospital, Changzhou, China.
  • Department of Medical Oncology, Changzhou Cancer Hospital, Changzhou, China.
  • Department of Pharmacy, Changzhou Cancer Hospital, Changzhou, China.
  • Department of Radiotherapy, Changzhou Cancer Hospital, Changzhou, China.

Zitieren

APA

Gao, X., He, G., Bi, Y., Luo, H., Wu, J., Zu, Y., Ji, Y., & Yu, J. (2026). Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1875749

Vancouver

Gao X, He G, Bi Y, Luo H, Wu J, Zu Y, et al. Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1875749

BibTeX
@article{Gao2026,
  author = {Gao, Xiaohuan and He, Guangzhao and Bi, Yanzhi and Luo, Hui and Wu, Jing and Zu, Yuanyuan and Ji, Yun and Yu, Jingping},
  title = {Effect of dosing interval on the pharmacokinetic interaction between montmorillonite powder and pyrotinib in rats},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1875749}
}
Kostenlos starten →